Acasti Pharma Inc.
ACSTOther · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $196,000 | — |
| Operating income | −$16.7M | −$12.9M | −$52.2M | −$15.6M | −$16.4M | −$24.4M |
| Net income | −$9.6M | −$12.9M | −$42.4M | −$9.8M | −$19.7M | −$25.5M |
| Total assets | $72.0M | $73.3M | $79.1M | $128.6M | $62.5M | $22.9M |
| Total liabilities | $5.4M | $11.6M | $11.2M | $20.4M | $6.8M | $9.9M |
| Equity | $66.6M | $61.7M | $68.0M | $108.3M | $55.7M | $13.0M |
| EPS (diluted) | $-0.79 | $-1.35 | $-5.71 | $-0.27 | — | — |
| Shares out. | 13.8M | 9.4M | 44.6M | 44.4M | 208.4M | 92.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −14.4%
- Return on assets
- −13.3%
- Return on capital (ROCE)
- −23.8%
- Liabilities / assets
- 7.5%
- Debt / equity
- 0.08×
- Book value / share
- $4.82
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 3.34safe
- Accruals / assets
- 7.4%moderate
- Piotroski F-Score
- 2/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 warning● 2 good- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Other material eventApr 27, 2026
- Other material eventApr 23, 2026
- Results of operationsFeb 12, 2026
- Director / officer changeJan 12, 2026
- Results of operations · Other material eventNov 13, 2025
- Other material eventOct 23, 2025
- Other material eventSep 18, 2025
- Shareholder voteSep 12, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13G/AApr 27, 2026
- 8-KApr 27, 2026
- 8-KApr 23, 2026
- SCHEDULE 13G/AFeb 17, 2026
- SCHEDULE 13G/AFeb 13, 2026
- 8-KFeb 12, 2026
- 10-QFeb 12, 2026
- SCHEDULE 13G/AJan 28, 2026
- 8-KJan 12, 2026
- 4FORM 4Jan 12, 2026
- 4FORM 4Jan 12, 2026
- 4FORM 4Jan 12, 2026
- 4FORM 4Jan 12, 2026
- 10-Q/A10Q/ANov 17, 2025
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.